341 related articles for article (PubMed ID: 33609962)
1. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
2. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.
Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ
J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116
[TBL] [Abstract][Full Text] [Related]
4. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH
Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639
[TBL] [Abstract][Full Text] [Related]
5. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
[TBL] [Abstract][Full Text] [Related]
6. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
[TBL] [Abstract][Full Text] [Related]
7. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
8. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084
[TBL] [Abstract][Full Text] [Related]
9. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.
Bendikov-Bar I; Ron I; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2011 Jan; 46(1):4-10. PubMed ID: 21106416
[TBL] [Abstract][Full Text] [Related]
11. The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
Maor G; Cabasso O; Krivoruk O; Rodriguez J; Steller H; Segal D; Horowitz M
Hum Mol Genet; 2016 Jul; 25(13):2712-2727. PubMed ID: 27162249
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
[TBL] [Abstract][Full Text] [Related]
13. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
[TBL] [Abstract][Full Text] [Related]
14. Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones.
Hoshikawa T; Watanabe T; Kotake M; Tiberghien N; Woo CK; Lewis S; Briston T; Koglin M; Staddon JM; Powney B; Schapira AHV; Takle AK
Bioorg Med Chem Lett; 2023 Feb; 81():129130. PubMed ID: 36640928
[TBL] [Abstract][Full Text] [Related]
15. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
[TBL] [Abstract][Full Text] [Related]
16. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
[TBL] [Abstract][Full Text] [Related]
17. Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S
Grigor'eva EV; Kopytova AE; Yarkova ES; Pavlova SV; Sorogina DA; Malakhova AA; Malankhanova TB; Baydakova GV; Zakharova EY; Medvedev SP; Pchelina SN; Zakian SM
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901867
[No Abstract] [Full Text] [Related]
18. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.
Siemeling O; Slingerland S; van der Zee S; van Laar T
BMC Neurol; 2024 May; 24(1):146. PubMed ID: 38693511
[TBL] [Abstract][Full Text] [Related]
19. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]